

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO SECTION 13A-16 OR 15D-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-41634

HUB Cyber Security Ltd.  
(Exact Name of Registrant as Specified in Its Charter)

2 Kaplan St.  
Tel Aviv 6473403, Israel  
+972-3-924-4074  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form-40.

Form 20-F

Form 40-F

---

---

## CONTENTS

### *Acquisition of Evofem Convertible Notes and Purchase Rights; Issuance of Securities*

On June 26, 2026, HUB Cyber Security Ltd. (the “Company”) entered into securities purchase agreements (each, a “Purchase Agreement” and, collectively, the “Purchase Agreements”) with certain holders (each, a “Seller” and, collectively, the “Sellers”) of senior subordinated convertible notes (the “Evofem Notes”) of Evofem Biosciences, Inc., a Delaware corporation (“Evofem”), and of certain purchase rights to acquire securities of Evofem (the “Purchase Rights”). Pursuant to the Purchase Agreements, the Company agreed to purchase from the Sellers all of their respective Evofem Notes and Purchase Rights, free and clear of liens, in exchange solely for the issuance of equity securities of the Company as described below.

The Evofem Notes acquired by the Company consist of Evofem’s senior subordinated convertible notes governed by a common form of note (the “SSN Notes” and the “Aditxt Notes”), comprising the exchanged senior subordinated convertible notes originally issued between December 2022 and September 2023 and restructured effective December 1, 2023 (maturing December 1, 2026), together with senior subordinated convertible notes issued in the same form maturing April 8, 2028 and June 26, 2028. The Evofem Notes are junior subordinated obligations of Evofem (subordinated in right of cash payment to Evofem’s senior secured notes and other senior debt obligations of Evofem), bear interest at 8% per annum compounding monthly (payable at maturity), and are convertible, at the holder’s election, into shares of Evofem common stock at a conversion price of \$0.0154 per share (subject to customary adjustment for stock splits, stock dividends, recapitalizations and similar events), subject to a 4.99 or 9.99% beneficial-ownership limitation. Based on the aggregate outstanding balance of the Evofem Notes acquired by the Company (approximately \$5,373,556), the Evofem Notes would be convertible into approximately 348,932,233 shares of Evofem common stock, without factoring in the beneficial-ownership limitation. The Purchase Rights acquired by the Company are exercisable for Evofem common stock at the same \$0.0154 per share price and, based on the aggregate amount of the Purchase Rights acquired (approximately \$10,153,890), would be exercisable into approximately 659,343,507 shares of Evofem common stock. In the aggregate, the Evofem Notes and Purchase Rights acquired by the Company would be convertible into, and exercisable for, approximately 1,008,275,740 shares of Evofem common stock (in each case before giving effect to any beneficial-ownership limitations and Evofem’s available authorized common stock), which if fully converted and exercised, will give the Company an 88% ownership of Evofem based on the current outstanding shares (or 14% on a fully diluted basis, assuming full issuance of all potential shares issuable for all convertible instruments outstanding).

The aggregate purchase price payable by the Company for the Evofem Notes and Purchase Rights was approximately \$49,331,891 (the “Purchase Price”), payable solely in ordinary shares of the Company, no par value (the “Ordinary Shares”), and/or pre-funded warrants to purchase Ordinary Shares (the “Pre-Funded Warrants” and, together with the Ordinary Shares issued as consideration, the “Consideration Shares”), and not in cash. The number of Consideration Shares issuable to each Seller is equal to such Seller’s portion of the Purchase Price divided by \$1.560 per share, the closing price of the Ordinary Shares on the Nasdaq Stock Market on June 24, 2026. As aggregate consideration under the Purchase Agreements, the Company issued 31,623,000 Consideration Shares (including the Ordinary Shares issuable upon exercise of the Pre-Funded Warrants).

Pursuant to the Purchase Agreements, the Consideration Shares were issued as Ordinary Shares except to the extent that such issuance would cause a Seller, together with its affiliates and any persons acting in concert with it, to beneficially own or hold in excess of 4.99% of the Company’s outstanding Ordinary Shares after giving effect to the issuance (the “Beneficial Ownership Limitation”), in which case the portion that would otherwise exceed the Beneficial Ownership Limitation was issued in the form of Pre-Funded Warrants. Accordingly, at the closing the Company issued an aggregate of 1,794,901 Ordinary Shares and issued Pre-Funded Warrants exercisable for an aggregate of 29,828,099 Ordinary Shares. The number of Ordinary Shares issued to any individual Seller was limited so that such Seller would not exceed the Beneficial Ownership Limitation (a maximum of 225,417 Ordinary Shares per Seller, based on 4,291,960 Ordinary Shares outstanding immediately prior to the issuance), with the balance of such Seller’s Consideration Shares issued in the form of Pre-Funded Warrants. Certain Sellers whose existing beneficial ownership already equaled or exceeded 4.99% received all of their Consideration Shares in the form of Pre-Funded Warrants.

Each Pre-Funded Warrant has an exercise price of \$0.001 per Ordinary Share, may be exercised on a cash or cashless basis, and is not exercisable to the extent the holder would exceed the Beneficial Ownership Limitation.

The Company has agreed to call a meeting of its shareholders as soon as reasonably practicable following the closing to approve (i) the full exercise of the Pre-Funded Warrants and the issuance of all Ordinary Shares issuable upon exercise thereof and (ii) an increase in the Company's authorized share capital sufficient to permit such issuance in full. Upon receipt of such shareholder approval, the 4.99% Beneficial Ownership Limitation applicable to the Pre-Funded Warrants will automatically be lifted, and the Pre-Funded Warrants will thereafter be exercisable in full in accordance with their terms.

The Consideration Shares, and the Ordinary Shares issuable upon exercise of the Pre-Funded Warrants, were offered and issued in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), provided by Section 4(a)(2) thereof (and/or Regulation S) promulgated thereunder, and will constitute "restricted securities." This Report on Form 6-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The foregoing description of the Purchase Agreements and the Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Purchase Agreement and the form of Pre-Funded Warrant, copies of which are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K and are incorporated herein by reference.

#### *Corporate Restructuring*

The Evofem transaction is the latest milestone in a comprehensive restructuring that the Company has implemented, during which the Board and management team have taken steps to improve liquidity, simplify the Company's organizational structure, cut operating costs and strengthen corporate governance.

As part of this plan, the Company has substantially reduced operating expenses, eliminating many external consultants and contractors and reducing headcount solely at the HUB level by approximately 50%. The Company has also engaged Deloitte to support its restructuring efforts, operational improvements and financial planning as it works to strengthen its balance sheet. Additionally, the Board continues to explore various strategic alternatives intended to maximize value for shareholders and position HUB for future growth. The Company believes the Evofem transaction reflects a first step in a disciplined approach to pursuing strategic opportunities while preserving liquidity.

On July 1, 2026, the Company issued a press release announcing the transactions described above. A copy of the press release is furnished as Exhibit 99.3 to this Report on Form 6-K.

The information in this Report on Form 6-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	<a href="#">Form of Purchase Agreement, dated as of June 26, 2026, by and among HUB Cyber Security Ltd. and the Sellers party thereto</a>
99.2	<a href="#">Form of Pre-Funded Warrant</a>
99.3	<a href="#">Press Release, dated July 1, 2026</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 1, 2026

**Hub Cyber Security Ltd.**

By: /s/ Limor Zur-Stoller  
Limor Zur-Stoller  
Chief Financial Officer

## SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on June 26, 2026 by and among HUB Cyber Security Ltd., a company organized under the laws of the State of Israel (“**Buyer**” or “**HUBC**”), and each of the holders of Notes (as defined below) that executes and delivers a Seller signature page to this Agreement (each, a “**Seller**” and, collectively, the “**Sellers**”). The Notes held by each Seller, such Seller’s Purchase Price and the number of Consideration Shares issuable to such Seller are set forth opposite such Seller’s name on Schedule A hereto. The obligations of the Sellers under this Agreement are several and not joint, and each reference in this Agreement to “**Seller**” means each Seller severally and solely with respect to itself and its Purchased Securities.

WHEREAS, each Seller is the holder of the senior subordinated convertible notes of Evofem Biosciences, Inc., a Delaware corporation (the “**Company**”) set forth opposite such Seller’s name on Schedule A hereto, which notes are convertible into shares of the Company’s common stock at a conversion price of \$0.0154 per share (subject to adjustment) and the documentation for which is included and described on Appendix A hereto (with respect to each Seller, such Seller’s “**Notes**”); and

WHEREAS, each Seller desires to sell to Buyer, and Buyer desires to purchase from such Seller, all of such Seller’s Notes (with respect to each Seller, such Seller’s “**Purchased Securities**”) on the basis of the representations, warranties and agreements contained in this Agreement, and upon the terms but subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the adequacy of which is hereby acknowledged, the parties hereto agree as follows:

1. **Purchase of Purchased Securities.**

- (a) **Purchase and Sale.** At the Closing, subject to the terms and conditions of this Agreement, Buyer shall purchase from each Seller, and each Seller (severally and not jointly) shall sell, assign, transfer and convey to Buyer, all of such Seller’s right, title and interest in and to such Seller’s Purchased Securities, free and clear of all Liens (other than applicable state and federal securities laws and Liens (as defined below) created by or imposed by Buyer), against payment by Buyer of such Seller’s Purchase Price. Each Seller’s “**Purchase Price**” with respect to each Seller is the amount set forth opposite such Seller’s name on Schedule A hereto, payable solely in ordinary shares of HUBC or pre-funded warrants exercisable for ordinary shares of HUBC (collectively, with respect to each Seller, such Seller’s “**Consideration Shares**”), with the number of Consideration Shares issuable to such Seller equal to such Seller’s Purchase Price divided by \$1.560 per share (the closing price of HUBC’s ordinary shares on the Nasdaq Stock Market on June 24, 2026) (the “**Per Share Price**”). Whether the Consideration Shares are issued in the form of ordinary shares or pre-funded warrants (or a combination thereof) shall be determined in accordance with Section 4 (Beneficial Ownership Limitation); *provided*, that the aggregate number of Consideration Shares (or any pre-funded warrants and the ordinary shares issuable upon exercise thereof) issued under this Agreement and all substantially concurrent agreements with other holders of the Company’s junior notes shall not exceed 40,000,000 HUBC ordinary shares. Each Seller’s Consideration Shares shall be issued and delivered to such Seller by Deposit/Withdrawal at Custodian (“**DWAC**”) in accordance with the instructions set forth on such Seller’s signature page. Buyer shall be obligated to fund each Seller’s Purchase Price at the Closing.
-

- (b) **Closing.** The closing of the purchase and sale of the Purchased Securities contemplated by this Agreement (the “**Closing**”) shall occur at such time and date designated by Buyer, but shall not occur later than June 29, 2026 (the “**Closing Date**”). All actions taken at the Closing shall be deemed to have occurred simultaneously.
- (c) **Closing Deliveries.** On the Closing Date, (i) Seller shall deliver the Purchased Securities, together with duly executed assignment and transfer documentation, to Buyer’s broker or custodian; and (ii) upon receipt thereof, Buyer shall issue and deliver the Consideration Shares to Seller as set forth in Section 1(a).
2. **Seller Representations and Warranties.** Each Seller, severally and not jointly and solely with respect to itself and its Purchased Securities, hereby represents, warrants and covenants to Buyer as follows as of the date hereof and as of the Closing Date:
- (a) Seller has all requisite corporate power, legal capacity and authority to enter into this Agreement and to assume and perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by Seller and constitutes a valid and legally binding agreement of Seller enforceable against Seller in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.
- (b) Seller has good and valid title to the Purchased Securities free and clear of any lien, mortgage, security interest, pledge, option, charge or encumbrance of any kind (“**Liens**”) (other than restrictions under applicable state and federal securities laws, and Liens created or imposed by Buyer). Delivery of the Purchased Securities to Buyer will pass to Buyer good and valid title to the Purchased Securities, free and clear of Liens other than the foregoing. Seller has paid any and all amounts and charges due and owing to the Company with respect to the Purchased Securities, and there are no unpaid amounts or charges claimed to be due to the Company from Seller with respect to the Purchased Securities.
- (c) There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency or self-regulatory organization or body pending or, to the knowledge of Seller, threatened against or affecting Seller that could reasonably be expected to have a material adverse effect on the ability of Seller to perform its obligations hereunder.
- (d) Except as otherwise expressly provided in this Agreement, no consent, approval, authorization, permit or waiver of, or notice to or filing with, any person or entity (including any governmental or quasi-governmental agency, commission, board, bureau or instrumentality) is necessary or required as to Seller in connection with the execution, delivery and performance by Seller of this Agreement and the sale by Seller of the Purchased Securities, or in order to constitute this Agreement a valid, binding and enforceable obligation of Seller in accordance with its terms.

- (e) Except as otherwise expressly provided in this Agreement, the execution and delivery by Seller of this Agreement, the sale by Seller of the Purchased Securities and the performance by Seller of its obligations under this Agreement do not and will not (i) result in a violation of the certificate of incorporation (including, without limitation, any certificate of designation contained therein), by-laws or certificate of incorporation of Seller, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under any agreement, indenture or instrument to which Seller is a party (including, without limitation, pursuant to any lock-up agreement, leak-out agreement or any other agreement with respect to the Purchased Securities to which Seller or any of its affiliates are a party), or (iii) violate or conflict with any law applicable to Seller, any order or judgment of any court or other agency of government applicable to Seller or any of Seller's assets or any contractual restriction binding on or affecting Seller or any of Seller's assets. None of the execution and delivery by Seller of this Agreement, the sale by Seller of the Purchased Securities and the performance by Seller of its obligations under this Agreement require Seller to obtain any consent, permit, waiver or other authorization or require Seller to provide any notice to or make any filing with any person or entity. Without limiting the generality of the foregoing, Seller hereby represents and warrants that the purchase and sale of the Purchased Securities are not restricted by any terms of any agreements between the Company and Seller.
- (f) Seller has taken no action that would give rise to any claim by any person for brokerage commissions, finder's fees or similar payments relating to this Agreement or the transactions contemplated hereby.
- (g) Seller is not selling the Purchased Securities "on the basis of" (as defined in Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) any material, non-public information about the Purchased Securities or the Company.
- (h) Seller is not an "affiliate" (as defined in Rule 144) of Buyer or a holder of "control" (as defined in Israeli Companies Law, 5759-1999) (the "Companies Law") of Buyer.

3. **Buyer Representations and Warranties.** Buyer hereby represents and warrants to Seller as follows as of the date hereof:

- (a) Buyer is a company duly organized and validly existing under the laws of the State of Israel, with full corporate power and authority to enter into and perform this Agreement and to issue the Consideration Shares. This Agreement has been duly authorized, executed and delivered by Buyer and constitutes a valid and binding obligation of Buyer enforceable against it in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors' rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

- (b) Buyer has adequate information concerning the business and financial condition of the Company to make an informed decision regarding the purchase of the Purchased Securities and has, independently and without reliance upon Seller or any of Seller's affiliates, employees or agents, and based on such information as Buyer has deemed appropriate, made its own analysis and decision to enter into this Agreement, except that Buyer has relied upon Seller's express representations, warranties and covenants in this Agreement. Buyer acknowledges that neither Seller nor any of Seller's affiliates, employees or agents has given Buyer any investment advice, credit information or opinion on whether the purchase of the Purchased Securities is prudent, and that neither Seller nor any of its affiliates, employees or agents is acting as a fiduciary for or an advisor to Buyer in respect of this Agreement.
- (c) Buyer understands that the Purchased Securities are being offered and sold to it in reliance on the representations and warranties contained in this Section 3 and pursuant to a specific exemption from the registration requirements of United States federal and state securities laws.
- (d) Buyer is an "accredited investor" as defined in Rule 501(a) under the Securities Act of 1933, as amended (the "Securities Act"), and is acquiring the Purchased Securities in a privately negotiated transaction exempt from the registration requirements of the Securities Act (Section 4(a)(2) and/or Regulation D), for its own account and for investment, and not with a view to, or for resale in connection with, any distribution thereof in violation of the Securities Act. Buyer has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of acquiring the Purchased Securities, has had access to such information regarding the Company and the Purchased Securities as it has requested, and is able to bear the economic risk of, and an entire loss of, its investment. Buyer understands that the Purchased Securities are "restricted securities," have not been registered under the Securities Act or any state securities laws, and may not be resold except pursuant to an effective registration statement or an available exemption from registration (including Rule 144).
- (e) Buyer is not purchasing the Purchased Securities "on the basis of" (as defined in Rule 10b5-1 of the Exchange Act) any material, non-public information about the Purchased Securities or the Company.
- (f) The Consideration Shares are either (i) ordinary shares, no par value, of Buyer or (ii) pre-funded warrants to purchase ordinary shares of Buyer, in each case as determined pursuant to Section 4 (Beneficial Ownership Limitation). The Consideration Shares and/or, if applicable, the ordinary shares underlying the pre-funded warrants constituting Consideration Shares, have been duly authorized and, when issued and delivered against the Purchased Securities in accordance with this Agreement, will be validly issued, fully paid and non-assessable (or the equivalent under the Companies Law, free and clear of Liens other than restrictions on transfer arising under applicable securities laws (including restricted-security legends and Rule 144 resale conditions) and any lock-up agreed in writing. The Consideration Shares will be issued in reliance on exemptions from registration under the Securities Act (Section 4(a)(2) and/or Regulation D) and will be "restricted securities."

4. **Beneficial Ownership Limitation.** Notwithstanding anything to the contrary contained herein, the number of ordinary shares of Buyer issuable to Seller upon this Agreement or upon exercise of any pre-funded warrants issued hereunder shall be limited to the extent necessary so that, after giving effect thereto, the aggregate number of ordinary shares of Buyer beneficially owned by Seller and its Affiliates (as defined in Rule 13d-3 of the Exchange Act) or “held” (as defined for purposes the Companies Law) does not exceed 4.99% of the number of ordinary shares of Buyer outstanding immediately after giving effect to such issuance (the “Beneficial Ownership Limitation”). For purposes of this Section 4, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and holdings shall be calculated in accordance with the Companies Law, as applicable (with the higher result governing any determination hereunder). To the extent that the Beneficial Ownership Limitation would be exceeded on the Closing Date by the issuance of Consideration Shares, the portion of the Consideration Shares that would otherwise cause Seller to exceed the Beneficial Ownership Limitation shall be issued in the form of pre-funded warrants exercisable for ordinary shares of Buyer (with an exercise price of \$0.001 per share), which pre-funded warrants shall not be exercisable to the extent that such exercise would cause Seller and its Affiliates to exceed the Beneficial Ownership Limitation. For the avoidance of doubt, if the Beneficial Ownership Limitation is exceeded prior to the Closing, then all the Consideration Shares issuable to Seller hereunder shall be issued in the form of pre-funded warrants described above. The provisions of this Section 4 shall be construed, corrected and implemented in a manner consistent with the intent of the parties to limit the beneficial ownership of Buyer’s ordinary shares by Seller to the Beneficial Ownership Limitation, and neither this Section 4 nor any portion hereof shall be interpreted otherwise.
5. **Shareholder Approval.** As soon as reasonably practicable following the Closing, Buyer shall call, and shall use its reasonable best efforts to convene and hold, a meeting of its shareholders (and to solicit and obtain the approval of its shareholders) for the purpose of approving (i) the full exercise of the pre-funded warrants issued pursuant to this Agreement (in the form attached hereto as Appendix B, the “Pre-Funded Warrants”) and the issuance of all ordinary shares of Buyer issuable upon the exercise thereof, and (ii) an increase in Buyer’s authorized share capital in an amount sufficient to permit such issuance in full (collectively, the “Shareholder Approval”). Upon the receipt of the Shareholder Approval, the 4.99% beneficial-ownership limitation applicable to the Pre-Funded Warrants shall automatically be lifted and shall cease to apply, and the Pre-Funded Warrants shall thereafter be exercisable in full without regard to such limitation, in accordance with their terms.
6. **Payment of Expenses.** Each party hereto shall be liable for its own costs and expenses in connection with the transactions contemplated hereby.

7. **Notices.** All communications hereunder shall be emailed and confirmed to the parties hereto as follows:

**If to Buyer:**

HUB Cyber Security Ltd.  
30 Hacharoshet Street  
Or Yehuda, Israel  
Attention: Tuvia Grossman, Chief Legal Officer  
Email: [\*]

with copies (which shall not constitute notice) to:

Honigman LLP  
660 Woodward Avenue, Suite 2290  
Detroit, Michigan 48226  
Attention: Michael J. Rosenberg  
Email: MRosenberg@honigman.com

and

Goldfarb Gross Seligman & Co.  
98 Yigal Alon Street  
Tel Aviv 6789141, Israel  
Attention: Adam Klein  
Email: adam.klein@goldfarb.com

**If to Seller:**

To each Seller, at the email address and other contact information set forth on such Seller's signature page hereto.

Any party hereto may change the email address for receipt of communications by giving email notice to the other party.

8. **Governing Law; Submission to Jurisdiction.** THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES. EACH PARTY AGREES THAT ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING IN ANY WAY TO THIS AGREEMENT SHALL BE BROUGHT IN A U.S. FEDERAL OR STATE COURT OF COMPETENT JURISDICTION SITTING IN THE COUNTY, CITY, AND STATE OF NEW YORK. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY CONSENTS TO THE JURISDICTION OF SUCH COURT AND HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY DEFENSE OF AN INCONVENIENT FORUM OR A LACK OF PERSONAL JURISDICTION TO THE MAINTENANCE OF ANY ACTION OR PROCEEDING AND ANY RIGHT OF JURISDICTION OR VENUE ON ACCOUNT OF THE PLACE OF RESIDENCE OR DOMICILE OF ANY PARTY HERETO. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
9. **Entire Agreement; Amendments.** This Agreement supersedes all other prior oral or written agreements among Buyer, Seller, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and contains the entire understanding of the parties with respect to such matters; except as specifically set forth herein, neither Seller nor Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision hereof may be amended or waived other than by an instrument in writing signed by the party against whom enforcement is sought.
10. **Severability.** If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.
11. **No Third Party Beneficiaries.** This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.
12. **Further Assurances.** Each party shall use its commercially reasonable efforts to do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
13. **Successors.** This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.

*[The remainder of this page is intentionally left blank; signature page follows]*

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

**BUYER:**

HUB CYBER SECURITY LTD.

By: \_\_\_\_\_  
Name:  
Title:

By: \_\_\_\_\_  
Name:  
Title:

**SELLER SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT**

By executing and delivering this signature page, the undersigned (i) agrees to become a party to, and to be bound by, that certain Securities Purchase Agreement, dated as of \_\_\_\_\_, 2026, by and among HUB Cyber Security Ltd. and the Sellers party thereto (the "Agreement"), as a "Seller" thereunder; (ii) adopts and agrees to be bound by Schedule A to the Agreement, including the Notes, Purchase Price and Consideration Shares set forth opposite its name therein; and (iii) makes, as of the date hereof and as of the Closing Date, the representations, warranties and covenants of a Seller set forth in the Agreement, severally and not jointly and solely with respect to itself and its Purchased Securities; and (iv) represents and warrants that the number of ordinary shares of HUB Cyber Security Ltd. beneficially owned or held, directly or indirectly, by the undersigned, together with its affiliates and any other persons acting in concert with the undersigned (within the meaning of Section 13(d) of the Exchange Act and the Israeli Companies Law, 1999), as of the date hereof is the number set forth below, undertakes to notify Buyer in writing promptly (and in any event prior to the Closing) of any change in such number, and covenants that it shall not increase such holdings prior to the Closing without Buyer's prior written consent. Capitalized terms used but not otherwise defined herein have the meanings given them in the Agreement.

**SELLER:**

\_\_\_\_\_

By: \_\_\_\_\_

Name:

Title:

Email for notices: \_\_\_\_\_

Address for notices: \_\_\_\_\_

Ordinary shares of HUB Cyber Security Ltd. held, directly or indirectly, by the Seller and its affiliates and persons acting in concert, as of the date hereof:

\_\_\_\_\_

Seller's DWAC instructions to Buyer:

\_\_\_\_\_

**SCHEDULE A**

## APPENDIX A

*Attached hereto are true, correct and complete copies of the following (collectively, the "Note Documents"): (i) each promissory note evidencing the Notes; (ii) the securities purchase agreement and related subscription documents pursuant to which the Notes were issued, in each case as amended, restated, supplemented or otherwise modified through the date hereof; and (iii) a schedule of the record holders of the Notes, setting forth the outstanding principal amount held by each, which evidences Seller's ownership of the Purchased Securities.*

**APPENDIX B**  
**FORM OF PRE-FUNDED WARRANT**

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), FROM REPUTABLE COUNSEL, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

HUB CYBER SECURITY LTD.

WARRANT TO PURCHASE ORDINARY SHARES

Date of Issuance: \_\_\_\_\_, 2026 (“**Issuance Date**”)

HUB Cyber Security Ltd., an Israeli company (the “**Company**”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, \_\_\_\_\_, the registered holder hereof or his permitted assigns (the “**Holder**”), is entitled, subject to the terms set forth below, to purchase from the Company, upon exercise of this Warrant to Purchase Ordinary Shares (including any Warrants to Purchase Ordinary Shares issued in exchange, transfer or replacement hereof, the “**Warrant**”), at any time or times on or after the Issuance Date, [●] (subject to adjustment as provided herein), fully paid and non-assessable Ordinary Shares (as defined below) (the “**Warrant Shares**”).

**1. EXERCISE OF WARRANT.**

- (a) Mechanics of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(c)), this Warrant may be exercised by the Holder on any day on or after the Issuance Date in whole or in part, by delivery (whether via facsimile or otherwise) of a written notice, in the form attached hereto as **Exhibit A** (the “**Exercise Notice**”), of the Holder’s election to exercise this Warrant. The Holder shall not be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original of this Warrant certificate and issuance of a new Warrant certificate evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant certificate after delivery of the Warrant Shares in accordance with the terms hereof. On or before the second (2<sup>nd</sup>) Trading Day following the date on which the Company has received such Exercise Notice, the Company shall instruct its transfer agent (the “**Transfer Agent**”), (i) provided that the Transfer Agent is participating in The Depository Trust Company (“**DTC**”) Fast Automated Securities Transfer Program (which the Company shall cause the Transfer Agent to do at Holder’s request) and provided the legends would be eligible to be removed from such Ordinary Shares in the discretion of the Company, upon the request of the Holder, to credit such aggregate number of Ordinary Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit/ Withdrawal at Custodian system, or (ii) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or the legends would not be eligible to be removed from such Ordinary Shares in the discretion of the Company, to issue and deliver to the Holder or, at the Holder’s instruction pursuant to the Exercise Notice, the Holder’s agent or designee, in each case, sent to the address as specified in the applicable Exercise Notice, a certificate or book entry position, in the name of the Holder or its designee (as indicated in the applicable Exercise Notice), for the number of Ordinary Shares to which the Holder is entitled pursuant to such exercise. Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates or book entry positions evidencing such Warrant Shares (as the case may be). If the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then, at the request of the Holder and upon surrender hereof by the Holder at the principal office of the Company, the Company shall as soon as practicable and in no event later than three (3) Business Days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 5(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional Ordinary Shares are to be issued upon the exercise of this Warrant, but rather the number of Ordinary Shares to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all taxes and fees which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.

- (b) Exercise Price; Pre-Funding. The exercise price per Warrant Share is \$0.001 (the “Exercise Price”), subject to adjustment as provided herein. This Warrant is pre-funded, such that the consideration for the Warrant Shares (other than the nominal Exercise Price) was paid in full on the Issuance Date, and this Warrant may be exercised by the Holder, in whole or in part from time to time, subject to the Maximum Percentage. The aggregate Exercise Price for the Warrant Shares being exercised shall be payable, at the Holder’s election, (i) in cash by wire transfer of immediately available funds, or (ii) by means of a cashless exercise, in which event the Holder shall be entitled to receive a number of Ordinary Shares equal to the product of (X) the number of Warrant Shares as to which this Warrant is being exercised multiplied by (Y) a fraction, the numerator of which is the Fair Market Value of one Ordinary Share on the date of the applicable Exercise Notice minus the Exercise Price, and the denominator of which is such Fair Market Value, such that no cash payment of the Exercise Price shall be required. For purposes hereof, “Fair Market Value” means the closing price of the Ordinary Shares on the Principal Market on the Trading Day immediately preceding the date of the applicable Exercise Notice.
- (c) Limitations on Exercises and Exchanges. Notwithstanding anything to the contrary contained in this Warrant, this Warrant shall not be exercisable or exchangeable by the Holder hereof to the extent (but only to the extent) that the Holder would hold (as defined for purposes of the Israeli Companies Law, 1999) or beneficially own (as defined for purposes of Section 13(d) of the 1934 Act) in excess of 4.99% of the number of Ordinary Shares outstanding after giving effect to the issuance of Ordinary Shares issuable upon exercise of the Warrant (the “**Maximum Percentage**”). No prior inability to exercise or exchange this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability or exchangeability. For the purposes of this paragraph, share holdings and all determinations and calculations (including, without limitation, with respect to calculations of percentage of holdings) shall be determined in accordance with the Israeli Companies Law, 1999 and with the U.S. Securities and Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; in the event of a conflict between such two laws, the stricter one shall govern. The provisions of this paragraph shall be implemented in a manner otherwise than in strict conformity with the terms of this paragraph to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Maximum Percentage limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such Maximum Percentage limitation. The limitations contained in this paragraph shall apply to a successor Holder of this Warrant. For any reason at any time, upon the written or oral request of the Holder, the Company shall within two (2) Business Days confirm in writing to the Holder the number of Ordinary Shares then outstanding, including by virtue of any prior conversion or exercise or exchange of convertible or exercisable or exchangeable securities into Ordinary Shares. The Maximum Percentage limitation shall not apply to the Holder if the Warrant is exercised and the Ordinary Shares are issued concurrently with the sale or cancellation of such Ordinary Shares upon the closing of an Exit Transaction.
- (d) Reservation of Shares; Insufficient Authorized Shares. The Company shall initially reserve out of its authorized and unissued Ordinary Shares a number of Ordinary Shares equal to the maximum number of Warrant Shares issuable to satisfy the Company's obligations to issue Ordinary Shares hereunder, and the Company shall at all times keep reserved for issuance under this Warrant a number of Ordinary Shares equal to the maximum number of Warrant Shares issuable to satisfy the Company’s obligation to issue Ordinary Shares hereunder.
- (e) Activity Restriction. For so long as the Holder holds this Warrant or any Warrant Shares, the Holder will not acquire additional securities of the Company, alone or together with any other Person, which, following the acquisition thereof, would result in holding, directly or indirectly, more than the Maximum Percentage, and any Ordinary Shares held by the Holder in excess thereof shall be dormant shares. For the avoidance of any doubt, the Holder may vote any Ordinary Shares held or controlled by it up to the Maximum Percentage, solicit any proxies, or seek to advise or influence any Person with respect to any voting securities of the Company, in its sole discretion.

- (f) No Short Sales. The Holder covenants that through and including the first Trading Day following the full exercise or termination of this Warrant, none of the Holder or any of its officers, or any entity managed or controlled by the Holder (each of the foregoing, a “**Restricted Person**”) shall, directly or indirectly, (i) engage in any “short sale” (as such term is defined in Rule 200 of Regulation SHO of the 1934 Act) of the Ordinary Shares or (ii) engage in any hedging transaction, which establishes a net short position with respect to any securities of the Company (including the Ordinary Shares), with respect to each of clauses (i) and (ii) hereof, either for its own principal account or for the principal account of any other Restricted Person.
- (g) Shareholder Approval. The Company shall call, and shall use its reasonable best efforts to convene and hold, a meeting of its shareholders as soon as reasonably practicable to approve the full exercise of this Warrant and the issuance of all Warrant Shares, together with an increase in the Company’s authorized share capital sufficient to permit such issuance in full (the “Shareholder Approval”). Notwithstanding anything to the contrary in this Warrant, upon the receipt of the Shareholder Approval, the Maximum Percentage limitation set forth in Section 1(c) shall automatically terminate and cease to apply, and this Warrant shall thereafter be exercisable in full without regard to the Maximum Percentage.
2. ADJUSTMENT TO NUMBER OF WARRANT SHARES. During such time as this Warrant is outstanding, the number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this Section 2.
- (a) Stock Dividends and Splits. If the Company, at any time on or after the Issuance Date of this Warrant, (i) distributes a stock dividend on one or more classes of its then outstanding Ordinary Shares or otherwise makes a distribution on any class of capital stock that is payable in Ordinary Shares, (ii) subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its then outstanding Ordinary Shares into a larger number of shares or (iii) combines (by combination, reverse stock split or otherwise) one or more classes of its then outstanding Ordinary Shares into a smaller number of shares, then in each such case the number of Warrant Shares that may be issued upon exercise of this Warrant shall be increased or decreased proportionately, as the case may be. Any of the adjustment set forth above shall become effective immediately after the effective date of the applicable event.
- (b) Calculations. All calculations under this Section 2 shall be made by rounding to the nearest 1/100<sup>th</sup> of a share. The number of Ordinary Shares outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Ordinary Shares.

3. NONCIRCUMVENTION. During such time as this Warrant is outstanding, the Company hereby covenants and agrees that the Company will not, by amendment of its articles of association or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Ordinary Shares upon the exercise of this Warrant, and (ii) shall, so long as the Warrant is outstanding, take all actions necessary to reserve and keep available out of its authorized and unissued Ordinary Shares, solely for the purpose of effecting the exercise of the Warrant, the maximum number of Ordinary Shares as shall from time to time be necessary to effect the exercise of the Warrant then outstanding; provided, however, that such amount of reserved Ordinary Shares shall be limited by the Maximum Percentage of Ordinary Shares as set forth in Section 1(c).
4. WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or other distributions, participate in or receive any rights, options or warrants offered to holders of Ordinary Shares (including in any rights offering), or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.
5. REISSUANCE OF WARRANTS.
- (a) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 5(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 5(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144 under the Securities Act, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, provide to the Company an opinion of counsel selected by the Holder, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred securities under the Securities Act.

- (b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 5(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.
- (c) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 5(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional Ordinary Shares shall be given.
- (d) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 5(a) or Section 5(c), the Warrant Shares designated by the Holder which, when added to the number of Ordinary Shares underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.
6. NOTICES. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) as soon as practicable upon each adjustment of the number of Warrant Shares in accordance with the terms of this Warrant, setting forth in reasonable detail, and certifying, the calculation of such adjustment(s) and (ii) at least two (2) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the Ordinary Shares, (B) with respect to any grants, issuances or sales of any rights to purchase shares, warrants, securities, indebtedness or other property pro rata to the holders of Ordinary Shares or (C) for determining rights to vote with respect to any Exit Transaction, dissolution or liquidation, provided in each case that such information, to the extent it constitutes, or contains, material, non-public information regarding the Company, shall be made known to the public prior to or in conjunction with such notice being provided to the Holder and (iii) at least two (2) Trading Days prior to the consummation of any Exit Transaction. It is expressly understood and agreed that the time of execution specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company. The Holder's address for the provision of notices to the Holder shall be provided in writing by the Holder to the Company, to the attention of its general counsel.

7. **AMENDMENT AND WAIVER.** Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder, provided that the Company may extend the Expiration Date without the consent of the Holder. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.
8. **SEVERABILITY.** If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
9. **GOVERNING LAW.** This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Israel, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdictions other than the State of Israel. The Company hereby irrevocably submits to the exclusive jurisdiction of the courts of Tel Aviv, Israel, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to enforce a judgment or other court ruling in favor of the Holder.

10. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.
11. REMEDIES, CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company's compliance with the terms and conditions of this Warrant (including, without limitation, compliance with Section 2 hereof). The issuance of shares as contemplated hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf.
12. TRANSFER. This Warrant may be offered for sale, sold, transferred or assigned by the Holder without the consent of the Company, provided that such sale, transfer or assignment of any of the Company's securities represented hereunder shall not be effected (i) in the absence of (a) an effective registration statement under the Securities Act of 1933, as amended, or applicable state securities laws, or (b) an opinion of counsel to the Holder, if requested by the Company, from reputable counsel, that registration is not required under such laws; or (ii) unless sold or eligible to be sold pursuant to Rule 144 under said Act.
13. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:
- (a) "**Business Day**" means any day other than Friday, Saturday, Sunday or other day on which commercial banks in New York, New York or Israel are authorized or required by law to remain closed.
  - (b) "**Convertible Securities**" means any stock or other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any Ordinary Shares.

- (c) “**Expiration Date**” means the date that is five years after the Issuance Date or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a “**Holiday**”), the next date that is not a Holiday, provided, however, that the Expiration Date shall be accelerated to the date of closing of an Exit Transaction.
- (d) “**Exit Transaction**” means a share purchase, merger or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other Person(s) whereby (i) such other Person(s) acquire (or otherwise becomes the holder, directly or indirectly, of) more than 80% of the outstanding shares of Voting Stock of the Company (not including any shares of Voting Stock of the Company held by the other Person(s) or other Person(s) making or party to, or associated or affiliated with the other Person(s) making or party to, such transaction) and (ii) the Company ceases to be a public company for purposes of the Israeli Companies Law, 1999.
- (e) “**Options**” means any rights, warrants or options to subscribe for or purchase Ordinary Shares or Convertible Securities.
- (f) “**Ordinary Shares**” means the ordinary shares, no par value per share, of the Company and any other shares issued or issuable with respect thereto (whether by way of a stock dividend or stock split or in exchange for or upon conversion of such shares or otherwise in connection with a combination of shares, distribution, recapitalization, merger, consolidation, other corporate reorganization or other similar event with respect to the Ordinary Shares).
- (g) “**Person**” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.
- (h) “**Principal Market**” means the Nasdaq Stock Market or, if such market is not the principal trading market for the Ordinary Shares, then on the principal securities exchange or securities market on which the Ordinary Shares is then traded.
- (i) “**Trading Day**” means, as applicable, (x) with respect to all price determinations relating to the Ordinary Shares, any day on which the Ordinary Shares is traded on the Principal Market, provided that “Trading Day” shall not include any day on which the Ordinary Shares are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Ordinary Shares are suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y) with respect to all determinations other than price determinations relating to the Ordinary Shares, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities.
- (j) “**Voting Stock**” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers or trustees of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might have voting power by reason of the happening of any contingency).

[Signature page follows]

IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Ordinary Shares to be duly executed as of the Issuance Date set out above.

**HUB CYBER SECURITY LTD.**

By: \_\_\_\_\_  
Name:  
Title:

By: \_\_\_\_\_  
Name:  
Title:

EXHIBIT A

EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS  
WARRANT TO PURCHASE ORDINARY SHARES

HUB CYBER SECURITY LTD.

The undersigned holder of the attached warrant (the “**Warrant**”) hereby exercises the right to purchase in respect of \_\_\_\_\_ Ordinary Shares (“**Warrant Shares**”) of HUB Cyber Security Ltd., an Israeli company (the “**Company**”). The undersigned holder hereby represents that the issuance of the Warrant Shares will not cause the undersigned holder’s holdings in the Company’s Ordinary Shares to exceed the Maximum Percentage, as defined in Section 1(c) of the Warrant, based on the number of outstanding Ordinary Shares provided to the holder by the Company in writing.

The aggregate Exercise Price shall be paid (check one): [ ] in cash by wire transfer of immediately available funds; or [ ] by cashless exercise pursuant to Section 1(b) of the Warrant.

Date: \_\_\_\_\_, \_\_\_\_\_

\_\_\_\_\_  
Name of Registered Holder

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

**EXHIBIT B**

**ACKNOWLEDGMENT**

The Company hereby acknowledges this Exercise Notice and hereby directs \_\_\_\_\_ to issue the above indicated number of Ordinary Shares.

**HUB CYBER SECURITY LTD.**

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

## HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround

*Move Expands HUB's Footprint Into Women's Health and Wellness, a Sector With Significant Commercial Revenue Potential, as Company Advances Broader Turnaround Strategy*

**Tel Aviv, Israel** – July 1, 2026 – **HUB Cyber Security Ltd.** (Nasdaq: HUBC) (“**HUB**” or the “**Company**”), today announced that it has acquired certain senior subordinated convertible notes and purchase rights of Evofem Biosciences, Inc. (OTCMKTS: EVFM) (“**Evofem**”), funded entirely with HUB equity at no cash cost to the Company. The transaction is the latest step in a broader transformation plan to strengthen HUB's financial position, streamline operations, enhance governance and build long-term shareholder value.

The notes and purchase rights were acquired directly from certain Evofem noteholders in exchange solely for HUB equity securities, consisting of ordinary shares and/or pre-funded warrants. By structuring the deal entirely in equity, HUB preserves its cash position while investing in a strategic business that the Company's Board of Directors (the “**Board**”) believes supports its broader repositioning and long-term value-creation efforts.

The Evofem transaction is the latest milestone in a comprehensive restructuring HUB has pursued over the past several months, during which the Board and management team have taken steps to improve liquidity, simplify the Company's organizational structure, cut operating costs and strengthen corporate governance. HUB also intends to explore opportunities to collaborate with Evofem going forward as part of that broader strategy.

As part of this plan, the Company has substantially reduced operating expenses, eliminating many external consultants and contractors and reducing headcount solely at the HUB level by approximately 50%. The Company has also engaged Deloitte to support its restructuring efforts, operational improvements and financial planning as it works to strengthen its balance sheet. Management believes these actions are creating a leaner, more focused organization positioned to execute on its highest-priority opportunities.

In parallel, the Board continues to explore various strategic alternatives intended to maximize value for shareholders and position HUB for future growth. The Company believes the Evofem transaction reflects a first step in a disciplined approach to pursuing strategic opportunities while preserving liquidity.

Renah Persofsky, Chair of HUB Cyber Security, commented: “HUB is taking bold and necessary steps to reshape the Company for its next chapter. The Evofem transaction demonstrates our ability to pursue strategic opportunities while preserving cash. Evofem reported north of \$20 million in sales in 2025. This comes alongside a broader restructuring program aimed at strengthening HUB's balance sheet and building a leaner, more strategically focused company. Together, these actions reflect a clear commitment by the Board and management team to position HUB for renewed momentum and long-term value creation.”

Ms. Persofsky continued: “While the Company has faced a challenging period, we believe the actions now underway will place HUB on a stronger and more sustainable path. We are concentrating our resources, attention and capital allocation around initiatives that we believe can deliver value for customers, employees and shareholders.”

### **About HUB Cyber Security Ltd.**

**HUB Cyber Security Ltd.** (Nasdaq: HUBC) is a global leader in confidential computing, AI-driven data fabric, and cybersecurity. HUB's Secured Data Fabric (SDF) empowers organizations to virtualize, secure, and analyze sensitive data across borders and silos generating real-time intelligence while meeting the highest regulatory standards. HUB partners with Fortune 100 companies and sovereign institutions to secure the next generation of digital infrastructure.

### **About Evofem Biosciences, Inc.**

**Evofem Biosciences, Inc.** (OTCMKTS: EVFM), a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Evofem's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem is headquartered in San Diego, California.

---

## **Forward-Looking Statements**

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “future,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “seem,” “should,” “will,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of HUB, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made with the SEC by HUB and the following: (i) the Company’s ability to meet stock exchange continued listing standards and remain listed on the Nasdaq; (ii) significant uncertainty regarding the adequacy of HUB’s liquidity and capital resources and its ability to repay its obligations as they become due; (iii) the war between Israel and Hamas commenced in October 2023 and the ensuing military action with Hezbollah and Iran, which may harm Israel’s economy and HUB’s business; (iv) expectations regarding HUB’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and HUB’s ability to invest in growth initiatives and pursue acquisition opportunities; (v) the outcome of any legal or regulatory proceedings against HUB in connection with our previously announced internal investigation or otherwise; (vi) competition, the ability of HUB to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (vii) limited liquidity and trading of HUB’s securities; (viii) geopolitical risk, including military action and related sanctions, and changes in applicable laws or regulations; (ix) the possibility that HUB may be adversely affected by other economic, business, and/or competitive factors; (x) the absence of a CEO since April 1, 2026, and (xi) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in HUB’s Annual Report on Form 20-F filed on May 1, 2025.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of HUB prove incorrect, actual results may vary in material respects from those expressed or implied in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning HUB or other matters addressed in this press release and attributable to HUB or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in the press release. Except to the extent required by applicable law or regulation, HUB undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events.

## **Investor Relations**

Lytham Partners  
Ben Shamsian  
646-829-9701  
shamsian@lythampartners.com

---